Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190490 | 1.00 | CA1 (0.33) | CA1CA2ACHECA12CA9 | |
| SCHEMBL9623348 | 1.00 | CA1 (0.33) | CA1CA2ACHECA12CA9 | |
| SCHEMBL13696645 | 1.00 | CA1 (0.33) | CA1CA2ACHECA12CA9 | |
| SCHEMBL191513 | 0.97 | ACHE (0.30) | ACHE | |
| Methane SCHEMBL29077722 | 0.94 | CYP19A1 (0.32) | CYP19A1NPC1 | |
| SCHEMBL2696797 | 0.91 | — | — | |
| SCHEMBL22959617 | 0.84 | — | — | |
| SCHEMBL21933618 | 0.84 | — | — | |
| SCHEMBL10202604 | 0.84 | — | — | |
| SCHEMBL11625556 | 0.82 | CA1 (0.33) | CA1CA2ACHECA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20180072667-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2018-03-15 | — | — | US | disclosed |
| US-9845292-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-12-19 | — | — | US | disclosed |
| US-9845292-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-12-19 | — | — | US | disclosed |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160289184-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2016-10-06 | — | — | US | disclosed |
| US-8748462-B2 | Spirocyclic GPR40 modulators | AMGEN INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120232062-A1 | AZAINDAZOLES TO TREAT FLAVIVIRIDAE VIRUS INFECTION | EIGER BIOPHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232062-A1 | AZAINDAZOLES TO TREAT FLAVIVIRIDAE VIRUS INFECTION | EIGER BIOPHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110190330-A1 | SPIROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | WARNER-LAMBERT COMPANY LLC | 2009-09-10 | — | — | US | disclosed |
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | WARNER-LAMBERT COMPANY LLC | 2009-09-10 | — | — | US | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | CA1 4760/4885CA2 2000/4885ACHE 4395/4885 |
| US-20120232062-A1 | AZAINDAZOLES TO TREAT FLAVIVIRIDAE VIRUS INFECTION | HAVCR2, AZI2, ZC3HAV1 | CA1 4879/4885CA2 4876/4885ACHE 3958/4885 |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | PC, GOT2, CS | CA1 520/4885CA2 186/4885ACHE 2345/4885 |
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | PIK3CA, PIK3CD, PIK3R5 | CA1 4846/4885CA2 4470/4885ACHE 3211/4885 |
| US-20180072667-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | FKBP5, FKBP1A, FKBP3 | CA1 4409/4885CA2 4872/4885ACHE 4329/4885 |
| US-20110190330-A1 | SPIROCYCLIC GPR40 MODULATORS | GPR119, GPR55, GPR65 | CA1 4260/4885CA2 1376/4885ACHE 4678/4885 |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | DRD4, ADORA1, ADORA3 | CA1 4219/4885CA2 3680/4885ACHE 1512/4885 |
| US-20160289184-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | FKBP5, FKBP1A, FKBP1B | CA1 4419/4885CA2 4871/4885ACHE 4550/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | CA1 3751/4885CA2 4495/4885ACHE 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.